The CP-012 tablet
Active ingredients: levodopa and carbidopa.
Design: tablet-in-tablet - an inner core with the active ingredients, surrounded by an outer layer that controls when release starts.
Release profile: delayed, dual-pulse release designed to deliver carbidopa and levodopa in the late night and early morning.
Administration: taken orally at bedtime, in addition to usual Parkinson's medication.

Xxxxxxxx xxxxx
xxxxxx
Confirmed in clinical studies
Using pharmacoscintigraphy - a small radioactive marker that can be followed by a gamma camera - we have shown in both healthy volunteers and people with Parkinson's that CP-012 releases its content at the intended time several hours after bedtime dosing. This translates into the expected delayed levodopa levels in the blood.
The OralogiK™ technology
CP-012 is formulated using OralogiK™, a tablet-in-tablet drug-delivery platform developed by BDD Pharma (Glasgow, UK). OralogiK™ allows timed and targeted release of one or more drugs.